Abstract
One of the keys to understanding many complex biological interactions, is the
role played by specific carbohydrates. This is glycobiology. While many
glycobiology-related products commercialized to date are detection and
analysis kits for analyzing glycoproteins and the extent of glycosylation, a
newer body of research is harnessing glycobiology to develop glycol-based
drugs, or glycotherapeutics.
The glycosylated therapeutics business is among the faster growing segments in
the drug industry, but the development of novel glycosylated therapies is only
in the early commercial stages. A variety of companies have development
programs for new glycosylated therapeutics underway to exploit the potential
of carbohydrate mimics for treating infectious and other diseases, surface
sugars modulation in cancer therapies, and other mechanisms for improving drug
delivery and pharmacokinetic profiles.
This market briefing analyzes the world market for glycosylated therapeutics,
a segment of glycobiology. The report generally reviews the nature and
direction of research, as well as future markets. This briefing also profiles
several companies involved in developing such products in the field. Market
forecasts in this report are based on an examination of current market
conditions and on investigations into the development of new products by key
companies. This information is also weighted with the projected timing and the
potential for receiving regulatory approvals to market products. The
information presented in this report is the result of data gathered from
company product literature and other corporate brochures and documents, as
well as information found in the scientific and trade press. In addition,
interviews were conducted with company executives, clinicians, researchers and
public health officials.
View Cart
